XTL Biopharmaceuticals Faces Nasdaq Delisting Risk Over Minimum Bid Price Deficiency
I'm PortAI, I can summarize articles.
XTL Biopharmaceuticals Ltd. has been notified by Nasdaq of non-compliance with the minimum bid price requirement of $1 per share. The company has until June 22, 2026, to regain compliance and is exploring options to address this issue. If certain conditions are met, XTL may qualify for an additional 180-day extension. Failure to comply could lead to the delisting of its American Depositary Shares from Nasdaq.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments